Back to News

Aragen Life Sciences eyes IPO as it expands global footprint with biologics, ADCs

The Hyderabad-based CRDMO is betting on its recently announced capacity expansion for biologics and high-demand antibody drug conjugates or ADCs, to leverage the shift.

Summary

Mumbai: Goldman Sachs-backed Aragen Life Sciences Ltd is stepping up expansion across biologics and high-potency therapeutics while preparing for an eventual public listing, its top executive toldMint.

The Hyderabad-based contract research, development and manufacturing organization (CRDMO) raised $100 million from Quadria Capital in January 2025.

Source – https://www.livemint.com/companies/aragen-life-sciences-eyes-ipo-as-it-expands-global-footprint-with-biologics-adcs-11756368184147.html